KalVista Pharmaceuticals ... (KALV)
10.85
-0.54 (-4.78%)
At close: Mar 03, 2025, 3:59 PM
10.87
0.18%
After-hours: Mar 03, 2025, 04:00 PM EST
KalVista Pharmaceuticals Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
| Revenue | n/a | n/a | n/a | 12.69M | 12.69M | 16.13M | 8.39M | 1.5M | 2.13M | 1.8M | 415K | 1.54M |
| Cost of Revenue | 86.17M | 802K | 743K | 651K | 40.19K | 35.02K | 18.24K | 12.67K | 14.66K | 8.29K | n/a | n/a |
| Gross Profit | -86.17M | -802K | -743K | 12.04M | 12.65M | 16.09M | 8.38M | 1.49M | 2.12M | 1.8M | 415K | 1.54M |
| Operating Income | -140.44M | -110.87M | -96.61M | -57.92M | -40.53M | -29.82M | -18.7M | -22.34M | -15.18M | -8.09M | -5.22M | -1.83M |
| Interest Income | n/a | 2.23M | 1.09M | 903K | 1.83M | 1.4M | 82K | 36K | 50K | 19K | 2K | 1K |
| Pretax Income | -135.1M | -92.91M | -82.34M | -46.24M | -29.24M | -20.69M | -15.8M | -18.6M | -11.44M | -7.23M | -5.68M | -2.05M |
| Net Income | -126.64M | -74.85M | -68.51M | -44.49M | -29.12M | -20.82M | -15.8M | -18.6M | -11.44M | -7.23M | -5.68M | -2.05M |
| Selling & General & Admin | 54.28M | 30.59M | 26.45M | 16.64M | 13.03M | 10.93M | 8.86M | 11.18M | 2.65M | 1.61M | 1.4M | 1.41M |
| Research & Development | 86.17M | 80.28M | 70.17M | 41.29M | 40.19M | 35.02M | 18.24M | 12.67M | 14.66M | 8.29M | 4.23M | 1.96M |
| Other Expenses | -86.17M | 15.64M | 14.72M | 9.93M | 9.83M | 7.68M | 4.39M | 2.33M | 2.03M | 844K | -59K | 35K |
| Operating Expenses | 54.28M | 110.87M | 96.61M | 57.92M | 53.22M | 45.95M | 27.1M | 23.84M | 17.31M | 9.89M | 5.63M | 3.37M |
| Interest Expense | n/a | n/a | 1.09M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 405K | 256K |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 140.44M | 110.87M | 96.61M | 57.92M | 53.22M | 45.95M | 27.1M | 23.84M | 17.31M | 9.89M | 5.63M | 3.37M |
| Income Tax | -8.45M | -18.05M | -13.83M | -1.75M | -124K | 124K | -1.33M | -5.11M | -5.41M | -863K | 462K | 220K |
| Shares Outstanding (Basic) | 36.79M | 27.89M | 24.47M | 19.09M | 17.75M | 15.08M | 10.32M | 9.71M | 4.77M | 1.17M | 724.8K | 724.8K |
| Shares Outstanding (Diluted) | 36.79M | 27.89M | 24.47M | 19.09M | 17.75M | 15.08M | 10.32M | 9.71M | 4.77M | 1.17M | 724.8K | 724.8K |
| EPS (Basic) | -3.44 | -2.68 | -2.8 | -2.33 | -1.64 | -1.38 | -1.53 | -1.92 | -2.4 | -6.17 | -7.83 | -2.83 |
| EPS (Diluted) | -3.44 | -2.68 | -2.8 | -2.33 | -1.64 | -1.38 | -1.53 | -1.92 | -2.4 | -6.17 | -7.83 | -2.83 |
| EBITDA | -134.28M | -92.11M | -81.6M | -45.59M | -40.02M | -29.44M | -18.52M | -22.3M | -15.15M | -8.05M | -5.25M | -1.76M |
| Depreciation & Amortization | 816K | 802K | 743K | 651K | 525K | 378K | 180K | 40K | 133K | 38K | 27K | 38K |